Practice Standards for the Use of Multimodality Neuromonitoring: A Delphi Consensus Process
Metrics
Details
- Title
- Practice Standards for the Use of Multimodality Neuromonitoring: A Delphi Consensus Process
- Creators
- Brandon ForemanGregory KapinosMark S WainwrightLaura B NgwenyaKristine H O'PhelanKerri L LaRovereMatthew P KirschenBrian AppavuChristos LazaridisAyham AlkhachroumCarolina B MacielEdilberto AmorimJason J ChangEmily J GilmoreEric S RosenthalSoojin Park
- Publication Details
- Critical care medicine
- Grant note
- U.S. Department of Defense: W81XWH-18-DMRDP-PTCRA National Institutes of Health: OD OT2OD032701 U.S. Department of Defense (DoD)Marinus PharmaceuticalsU.S. ArmyUCB PharmaSAGE TherapeuticsAbbottBiogenGeneral Dynamics Information Technology/DoDBard Medical CECU.S. National Phase Applications: 17/601, 603, US-2022-0181008-A1, 21233 CMCC, 3440 WGS, M0437.70143US01 U.S. DoD Congressionally Directed Medical Research ProgramsAmerican Heart Association (AHA)National Institutes of Health (NIH)AHA: 20CDA35310297, 83457 CURE Epilepsy Foundation (Taking Flight Award)NIH: 1K23NS090900, UG3 NS123307 Hellman Fellows FundRegents of the University of California (Resource Allocation Program)Cures Within ReachZoll FoundationAmerican Academy of Neurology and Caring Analytics Platform (CARPL.ai)Moberg AnalyticsAmerican Heart Association (AHA): 20CDA35310297
Funding was provided by U.S. Department of Defense (W81XWH-18-DMRDP-PTCRA; to Drs. Foreman and Rosenthal) and by the National Institutes of Health (OD OT2OD032701; to Dr. Rosenthal).Dr. Foreman's institution received funding from the U.S. Department of Defense (DoD) (W81XWH-18-DMRDP-PTCRA); he received funding from Marinus Pharmaceuticals; he disclosed that he is on the Scientific Advisory Committee for the Neurocritical Care Society Curing Coma Campaign. Drs. Foreman and Appavu perform dedicated neuromonitoring services locally. Drs. Foreman and Rosenthal received Institutional support through U.S. Army W81XWH-18-DMRDP-PTCRA through parent award to Moberg Analytics. Drs. Foreman and Gilmore received funding from UCB Pharma. Drs. Foreman and Wainwright received funding from SAGE Therapeutics. Dr. Ngwenya's institution received funding from Abbott and Biogen; she received funding from General Dynamics Information Technology/DoD. Dr. O'Phelan received funding from Bard Medical CEC. Dr. La Rovere disclosed that she has U.S. National Phase Applications (No.: 17/601, 603, No.: US-2022-0181008-A1, Ref. No.: 21233 CMCC, Ref. No.: 3440 WGS, Ref. No.: M0437.70143US01 Patent-Issued). Dr. Appavu's institution received funding from the U.S. DoD Congressionally Directed Medical Research Programs and the American Heart Association (AHA). Drs. Alkhachroum and Rosenthal received support for article research from the National Institutes of Health (NIH). Dr. Amorim received funding from the AHA (20CDA35310297, 83457), the CURE Epilepsy Foundation (Taking Flight Award), the NIH (1K23NS090900), the Hellman Fellows Fund, the Regents of the University of California (Resource Allocation Program), Cures Within Reach, and the Zoll Foundation. Dr. Gilmore received funding from the American Academy of Neurology and Caring Analytics Platform (CARPL.ai); she serves as Director of Neuromonitoring locally; co-founded Intracranial Bio Analytics; and holds NIH grant funding for development of a multimodal intracranial monitoring device and data visualization platform (UG3 NS123307). Dr. Rosenthal's institution received funding from the NIH, the U.S. Army, Moberg Analytics, and Marinus Pharmaceuticals. The remaining authors have disclosed that they do not have any potential conflicts of interest.
- Academic Unit
- Miller School of Medicine; UMMG Department of Neurology; UMMG Dept of Neurology - Neurocritical Care Div
- Language
- English
- Resource Type
- Journal article
- PMID
- 37607072
- Record Identifier
- 991031927084202976